** Shares of Australia's LTR Pharma LTP.AX rise as much as 10.4% to A$0.425, their highest levels since May 2
** The biopharmaceutical firm signs a collaborative agreement with Strategic Drug Solutions
** The agreement is to co-develop OROFLOW, a novel intranasal spray targeting Oesophageal Motility Disorders - a group of conditions that cause impaired swallowing
** Stock has fallen 52.5% so far this year
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.